- Home
- JMM vs SCLX Comparison
JMM vs SCLX Comparison
Compare JMM & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- SCLX
- Stock Information
- Founded
- JMM 1988
- SCLX 2011
- Country
- JMM United States
- SCLX United States
- Employees
- JMM N/A
- SCLX N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- SCLX Health Care
- Exchange
- JMM Nasdaq
- SCLX Nasdaq
- Market Cap
- JMM 57.2M
- SCLX 51.3M
- IPO Year
- JMM N/A
- SCLX N/A
- Fundamental
- Price
- JMM $6.12
- SCLX $4.01
- Analyst Decision
- JMM
- SCLX Strong Buy
- Analyst Count
- JMM 0
- SCLX 4
- Target Price
- JMM N/A
- SCLX $396.67
- AVG Volume (30 Days)
- JMM 16.1K
- SCLX 204.4K
- Earning Date
- JMM 01-01-0001
- SCLX 05-16-2025
- Dividend Yield
- JMM 5.44%
- SCLX N/A
- EPS Growth
- JMM N/A
- SCLX N/A
- EPS
- JMM N/A
- SCLX N/A
- Revenue
- JMM N/A
- SCLX $56,590,000.00
- Revenue This Year
- JMM N/A
- SCLX $115.30
- Revenue Next Year
- JMM N/A
- SCLX $73.33
- P/E Ratio
- JMM N/A
- SCLX N/A
- Revenue Growth
- JMM N/A
- SCLX 21.07
- 52 Week Low
- JMM $5.29
- SCLX $3.60
- 52 Week High
- JMM $6.10
- SCLX $80.50
- Technical
- Relative Strength Index (RSI)
- JMM 54.56
- SCLX 30.93
- Support Level
- JMM $5.97
- SCLX $4.51
- Resistance Level
- JMM $6.16
- SCLX $6.13
- Average True Range (ATR)
- JMM 0.09
- SCLX 0.82
- MACD
- JMM 0.02
- SCLX 0.10
- Stochastic Oscillator
- JMM 85.19
- SCLX 16.20
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.